Drug Profile

C-SiPLK1-NP - PDX Pharmaceuticals

Alternative Names: PETTRA; PLK1 and EGFR Targeted Therapy and Radiation sensitizer - PDX Pharmaceuticals

Latest Information Update: 26 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PDX Pharmaceuticals
Class Antineoplastics; Monoclonal antibodies; Small interfering RNA
Mechanism of Action Polo like kinase 1 expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Jun 2023 Pharmacodynamics data from preclinical trial in Solid tumours released by PDX Pharmaceuticals (PDX Pharmaceuticals pipeline, June 2023)
23 Jun 2023 Preclinical trials in Solid tumours in USA (Parenteral) (PDX Pharmaceuticals pipeline, June 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com